



9 August 2018

Motif Bio plc
("Motif Bio" or the "Company")

Motif Bio to Present at Investor Events in August and September

Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company will participate at the following investor events in August and September.

8th Annual Solebury Trout Hamptons CEO Roundtable

August 16, 2018

Bridgehampton, NY

Graham Lumsden, Chief Executive Officer, will make a presentation on the Company and its product candidate, iclaprim, for which a New Drug Application (NDA) has recently been submitted. Motif Bio will also participate in one-on-one meetings during the event.

H.C. Wainwright 20th Annual Global Investment Conference

September 4-6, 2018

New York, NY

Management will provide a corporate overview on Thursday, September 6 at 10:25 AM ET. The presentation will be webcast, available live, and as a replay in the [Investors](#) section of the Company's website. Motif Bio will also participate in one-on-one meetings during the event.

For further information please contact:

Motif Bio plc

Graham Lumsden (Chief Executive Officer)

info@motifbio.com

Walbrook PR Ltd. (UK FINANCIAL PR & IR)

Paul McManus/Helen Cresswell/Lianne Cawthorne

+44 (0) 20 7933 8780

MC Services AG (EUROPEAN IR)

Raimund Gabriel

+49 (0)89 210 2280
raimund.gabriel@mc-services.eu

Solebury Trout (U.S. IR)

Meggie Purcell

+ 1 (646) 378-2963
mpurcell@troutgroup.com

Russo Partners (U.S. PR)

David Schull
Travis Kruse, Ph.D.

+1 (858) 717-2310 or +1 (212) 845 4272
david.schull@russopartnersllc.com
travis.kruse@russopartnersllc.com

Note to Editors:

About Motif Bio

Motif Bio plc (AIM/NASDAQ: MTFB) is a clinical-stage biopharmaceutical company focused on developing novel antibiotics for hospitalised patients and designed to be effective against serious and life-threatening

infections caused by multi-drug resistant Gram-positive bacteria, including MRSA. The Company's lead product candidate is iclaprim. Following positive results from two Phase 3 trials (REVIVE-1 and REVIVE-2), a New Drug Application (NDA) has been submitted to the U.S. Food & Drug Administration (FDA) for the treatment of acute bacterial skin and skin structure infections (ABSSSI). More than 3.6 million patients with ABSSSI are hospitalised annually in the U.S. It is estimated that up to 26% of hospitalized ABSSSI patients have renal impairment.

The Company also plans to develop iclaprim for hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), as there is a high unmet need for new therapies in this indication. A Phase 2 trial in patients with HABP has been successfully completed and a Phase 3 trial is being planned. Additionally, iclaprim has been granted orphan drug designation by the FDA for the treatment of *Staphylococcus aureus* lung infections in patients with cystic fibrosis and is in preclinical development for this indication.

Iclaprim has received Qualified Infectious Disease Product (QIDP) designation from the FDA together with Fast Track status. Upon acceptance by the FDA of an NDA, iclaprim will receive Priority Review status and, if approved as a New Chemical Entity, will be eligible for 10 years of market exclusivity in the U.S. from the date of first approval, under the Generating Antibiotic Incentives Now Act (the GAIN Act). In Europe, 10 years of market exclusivity is anticipated.

Forward-Looking Statements

This press release contains forward-looking statements. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Motif Bio's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Motif Bio believes that these factors include, but are not limited to, (i) the timing, progress and the results of clinical trials for Motif Bio's product candidates, (ii) the timing, scope or likelihood of regulatory filings and approvals for Motif Bio's product candidates, (iii) Motif Bio's ability to successfully commercialise its product candidates, (iv) Motif Bio's ability to effectively market any product candidates that receive regulatory approval, (v) Motif Bio's commercialisation, marketing and manufacturing capabilities and strategy, (vi) Motif Bio's expectation regarding the safety and efficacy of its product candidates, (vii) the potential clinical utility and benefits of Motif Bio's product candidates, (viii) Motif Bio's ability to advance its product candidates through various stages of development, especially through pivotal safety and efficacy trials, (ix) Motif Bio's estimates regarding the potential market opportunity for its product candidates, and (x) the factors discussed in the section entitled "Risk Factors" in Motif Bio's Annual Report on Form 20-F filed with the SEC on April 10, 2018, which is available on the SEC's web site, www.sec.gov. Motif Bio undertakes no obligation to update or revise any forward-looking statements.